Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis

CONCLUSIONS: Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.PMID:37393121 | DOI:10.1016/j.clml.2023.06.002

Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Salomon Manier Meletios Dimopoulos Cyrille Hulin Xavier Leleu Michel Delforge Katja Weisel Jorge Mouro Bruno Costa Michael Sturniolo Thierry Facon Source Type: research